In the ongoing Phase 1 dose-escalation trial of ERAS-0015, Erasca has observed multiple confirmed and unconfirmed partial responses across a variety of RAS-mutant solid tumors at doses as low as 8 mg once daily. Two confirmed partial responses and one unconfirmed response were seen at that dose level, with responses emerging at merely one-tenth of the exposure required by a comparable RAS-targeting agent. Across all dose cohorts, no dose-limiting toxicities have been reported, and adverse events have been predominantly low grade. Pharmacokinetic analyses demonstrate predictable, dose-proportional exposure, and enrollment is ahead of schedule, positioning Erasca to present initial monotherapy data in the first half of 2026 and to initiate expansion and combination cohorts in the second half of the year.

On January 7, 2026, Garner Ebun, Erasca’s general counsel and corporate secretary, exercised options on 120,000 shares and sold them immediately for gross proceeds of approximately $670,800. Following the transaction, her direct common stock holdings declined from 145,076 to 25,076 shares, representing an 82.7% reduction in direct ownership. Ebun retains 360,000 outstanding options, both vested and unvested, ensuring she remains aligned with the company’s long-term value creation. The sale was conducted under a pre-existing Rule 10b5-1 plan, and no indirect holdings or gift transactions were involved.